November 14, 2017
Novartis to present new data about broad range of breast cancer
Novartis announced it would present data across its breast cancer portfolio and pipeline in a broad range of patient populations,…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: cancer
October 24, 2017
Telix, ANMI in JV to sell imaging prostate cancer technology
Telix Pharmaceuticals Limited focused on on targeted radiopharmaceuticals or molecularly-targeted radiation (MTR), has partnered up with Advanced Nuclear Medicine Ingredients SA (ANMI).…
October 11, 2017
U.S. FDA fast tracks Astellas’s development of gilteritinib in certain myeloid leukemia
Astellas Pharma will have an expedited review process for gilteritinib, as the U.S. Food and Drug Administration (FDA) granted fast track…
October 10, 2017
Diplomat to sell Eli Lilly’s new cancer drug
Diplomat Pharmacy will dispense newly approved Eli Lilly’s Verzenio(abemaciclib), a twice-daily oral therapy for advanced breast cancer. Verzenio is indicated…
October 10, 2017
Lilly’s Verzenio failed to treat advanced non-small lung cancer
Eli Lilly’s Phase 3 JUNIPER study evaluating Verzenio (abemaciclib), a cyclin-dependent kinase (CDK)4 and CDK6 inhibitor, as monotherapy in KRAS-mutated, advanced…
October 9, 2017
AstraZeneca’s Tagrisso gets BTD for certain lung cancer
AstraZeneca Monday said that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the…
September 28, 2017
Novartis and UC Berkeley collaborate to tackle ‘undruggable’ disease targets
Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics, pursuing the vast number of disease targets in cancer and other illnesses that have eluded traditional small-molecule compounds and are considered “undruggable.”
September 25, 2017
Targovax protects its neoantigen vaccines in USA for RAS-mutated cancers
Targovax has obtained the patent from the US Patent and Trademark Office for it’s mutant-RAS specific neoantigen vaccines, TG01 and…
September 20, 2017
EC approves Novartis’s cancer drug for 2 indications
The European Commission has approved Novartis’s Rydapt for two indications in rare cancers, in combination with standard daunorubicin and cytarabine…
August 30, 2017
Historic moment in cancer treatment for Novartis
US Food and Drug Administration (FDA) has approved Novartis’s Kymriah suspension for intravenous infusion, formerly CTL019, the first chimeric antigen…